Home > Resources > Whitepapers > Jatropha curcas: Using Breeding and Biotechnology to Develop a New Alternative for Plant Oil, Biomass and Protein

Jatropha curcas: Using Breeding and Biotechnology to Develop a New Alternative for Plant Oil, Biomass and Protein

Over the course of the past seven years, SGB has succeeded in developing hybrids of Jatropha that are delivering per acre production in excess of 300 gallons of oil, 20 MT of green biomass and 0.6 MT of high quality protein per yeari . This document outlines the path leading to that success, and the reasons for Jatropha’s past failures.

Spotlight

BlueGranite

Our thought-leader mindset helps you easily identify high-impact issues and solve them with an experienced team of data and analytics professionals that can help you deliver value quickly. Our consultants put their extensive data engineering plus data science experience to work to plan and build solutions for industries ranging from retail and healthcare, to manufacturing and consumer goods.

OTHER WHITEPAPERS

BLOCKCHAIN ENABLED GENOME SECURITY FROM THE MOMENT IT IS SEQUENCED

whitePaper | June 8, 2022

Sequencing of human genomes is fast becoming an affordable technology for general consumer.

State of the Global Biotech Landscape

whitePaper | November 22, 2022

Over the last five years, the global biotech and pharmaceutical landscape has witnessed continued growth. The analysis period encompasses a unique timeframe including the global COVID-19 pandemic.

How advanced purification technologies are speeding the hunt for new protections against disease

whitePaper | November 24, 2022

Smallpox was the first infectious disease for which an effective vaccine was developed. In the late 1700s, British doctor Edward Jenner devised a method to inoculate people with cowpox pus to give them immunity against smallpox, a much more deadly disease.

COVID-19 Vaccines Production and Analytical Chemistry Solutions

whitePaper | February 2, 2022

Vaccines work by preparing a person’s immune system to recognize and defend itself against a specific disease.

Harnessing the power of the human microbiome

whitePaper | January 20, 2023

We provide an overview of the human microbiome market, the observed challenges, how to overcome them and introduce future opportunities for pharmaceutical.

Are Nitrosamines a Concern for Biologic Manufacturers?

whitePaper | March 30, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk.